Abbott Laboratories (MEX:ABT) Cyclically Adjusted Revenue per Share: MXN438.60 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ABT Abbott Laboratories MEX:ABT
81 GF Score
Price MXN1,620.85
GF Value MXN2,295.51
Valuation Modestly Undervalued
View Full Analysis

What is Abbott Laboratories Cyclically Adjusted Revenue per Share?

Abbott Laboratories MEX:ABT -1.23% 81 Cyclically Adjusted Revenue per Share is MXN438.60 as of Mar. 2026. GuruFocus rates MEX:ABT with a GF Score™ of 81/100 and a GF Value™ of MXN2,295.51 (Modestly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Abbott Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was MXN115.231. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN438.60 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Abbott Laboratories's average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Abbott Laboratories was 9.90% per year. The lowest was -1.70% per year. And the median was 7.70% per year.

As of today (2026-07-14), Abbott Laboratories's current stock price is MXN1620.85. Abbott Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN438.60. Abbott Laboratories's Cyclically Adjusted PS Ratio of today is 3.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Abbott Laboratories was 8.42. The lowest was 2.21. And the median was 5.08.


Abbott Laboratories  (MEX:ABT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Abbott Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1620.85/438.60
=3.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Abbott Laboratories was 8.42. The lowest was 2.21. And the median was 5.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Abbott Laboratories Cyclically Adjusted Revenue per Share Related Terms


Abbott Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Cyclically Adjusted Revenue per Share Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 372.11 383.37 341.54 468.40 433.38

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 461.08 448.28 437.38 433.38 438.60

MEX:ABT vs SYK, MDT, BSX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Abbott Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbott Laboratories Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Abbott Laboratories's Cyclically Adjusted PS Ratio falls into.


MEX:ABT
81GF Score
Abbott Laboratories MEX:ABT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Abbott Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=115.231/330.2130*330.2130
=115.231

Current CPI (Mar. 2026) = 330.2130.

Abbott Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 66.617 241.018 91.270
201609 69.439 241.428 94.975
201612 74.093 241.432 101.339
201703 68.743 243.801 93.108
201706 68.598 244.955 92.474
201709 70.651 246.819 94.522
201712 84.806 246.524 113.596
201803 76.055 249.554 100.637
201806 86.276 251.989 113.058
201809 80.830 252.439 105.733
201812 85.951 251.233 112.971
201903 82.273 254.202 106.874
201906 86.037 256.143 110.917
201909 89.362 256.759 114.927
201912 88.012 256.974 113.096
202003 101.742 258.115 130.161
202006 94.757 257.797 121.375
202009 109.389 260.280 138.780
202012 118.895 260.474 150.728
202103 119.303 264.877 148.731
202106 113.479 271.696 137.920
202109 125.602 274.310 151.199
202112 132.005 278.802 156.347
202203 133.466 287.504 153.293
202206 128.277 296.311 142.954
202209 118.729 296.808 132.092
202212 112.262 296.797 124.901
202303 100.296 301.836 109.725
202306 97.736 305.109 105.778
202309 101.059 307.789 108.422
202312 99.574 306.746 107.192
202403 94.513 312.332 99.924
202406 108.561 314.175 114.103
202409 119.825 315.301 125.492
202412 131.256 315.605 137.331
202503 121.282 319.799 125.231
202506 119.826 322.561 122.669
202509 119.218 324.800 121.205
202512 118.272 324.054 120.520
202603 115.231 330.213 115.231

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN438.60 mean?
Abbott Laboratories (MEX:ABT) has a Cyclically Adjusted Revenue per Share of MXN438.60 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Cyclically Adjusted Revenue per Share too high?
Abbott Laboratories' current Cyclically Adjusted Revenue per Share is MXN438.60. Overall, Abbott Laboratories has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Cyclically Adjusted Revenue per Share compare to SYK and MDT?
Abbott Laboratories' Cyclically Adjusted Revenue per Share of MXN438.60 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Cyclically Adjusted Revenue per Share is MXN438.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN2,295.51, compared to a current price of MXN1,620.85 — trading 29.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN438.60. Abbott Laboratories' overall GF Score™ is 81/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current Cyclically Adjusted Revenue per Share is MXN438.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of MXN1,620.85 is trading 29.4% below its estimated GF Value™ of MXN2,295.51. GuruFocus considers Abbott Laboratories to be Modestly Undervalued.

Key valuation signals for MEX:ABT:

  • Cyclically Adjusted Revenue per Share: MXN438.60
  • GF Value™: MXN2,295.51 vs. price of MXN1,620.85 (29.4% below fair value)
  • GF Score™: 81/100

No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
81GF Score

Get the complete analysis for MEX:ABT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,620.85
Price
MXN2,295.51
GF Value